Overcoming BET inhibitor resistance in malignant peripheral nerve sheath tumors

Jonathan M. Cooper, Amish J. Patel, Zhiguo Chen, Chung Ping Liao Ph.D., Kun Chen, Juan Mo, Yong Wang, Lu Q Le

Research output: Contribution to journalArticle

Abstract

Purpose: BET bromodomain inhibitors have emerged as a promising therapy for numerous cancer types in preclinical studies, including neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumor (MPNST). However, potential mechanisms underlying resistance to these inhibitors in different cancers are not completely understood. In this study, we explore new strategy to overcome BET inhibitor resistance in MPNST. Experimental Design: Through modeling tumor evolution by studying genetic changes underlying the development of MPNST, a lethal sarcoma with no effective medical treatment, we identified a targetable addiction to BET bromodomain family member BRD4 in MPNST. This served as a controlled model system to delineate mechanisms of sensitivity and resistance to BET bromodomain inhibitors in this disease. Results: Here, we show that a malignant progression–associated increase in BRD4 protein levels corresponds to partial sensitivity to BET inhibition in MPNST. Strikingly, genetic depletion of BRD4 protein levels synergistically sensitized MPNST cells to diverse BET inhibitors in culture and in vivo. Conclusions: Collectively, MPNST sensitivity to combination genetic and pharmacologic inhibition of BRD4 revealed the presence of a unique addiction to BRD4 in MPNST. Our discovery that a synthetic lethality exists between BET inhibition and reduced BRD4 protein levels nominates MPNST for the investigation of emerging therapeutic interventions such as proteolysis-targeting chimeras (PROTACs) that simultaneously target bromodomain activity and BET protein abundance.

Original languageEnglish (US)
Pages (from-to)3404-3416
Number of pages13
JournalClinical Cancer Research
Volume25
Issue number11
DOIs
StatePublished - Jun 1 2019

Fingerprint

Neurilemmoma
Proteins
Neoplasms
Neurofibromatosis 1
Molecular Evolution
Sarcoma
Proteolysis
Research Design
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Overcoming BET inhibitor resistance in malignant peripheral nerve sheath tumors. / Cooper, Jonathan M.; Patel, Amish J.; Chen, Zhiguo; Liao Ph.D., Chung Ping; Chen, Kun; Mo, Juan; Wang, Yong; Le, Lu Q.

In: Clinical Cancer Research, Vol. 25, No. 11, 01.06.2019, p. 3404-3416.

Research output: Contribution to journalArticle

Cooper, Jonathan M. ; Patel, Amish J. ; Chen, Zhiguo ; Liao Ph.D., Chung Ping ; Chen, Kun ; Mo, Juan ; Wang, Yong ; Le, Lu Q. / Overcoming BET inhibitor resistance in malignant peripheral nerve sheath tumors. In: Clinical Cancer Research. 2019 ; Vol. 25, No. 11. pp. 3404-3416.
@article{abafeb1175624b92a815f0d6c1d49f65,
title = "Overcoming BET inhibitor resistance in malignant peripheral nerve sheath tumors",
abstract = "Purpose: BET bromodomain inhibitors have emerged as a promising therapy for numerous cancer types in preclinical studies, including neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumor (MPNST). However, potential mechanisms underlying resistance to these inhibitors in different cancers are not completely understood. In this study, we explore new strategy to overcome BET inhibitor resistance in MPNST. Experimental Design: Through modeling tumor evolution by studying genetic changes underlying the development of MPNST, a lethal sarcoma with no effective medical treatment, we identified a targetable addiction to BET bromodomain family member BRD4 in MPNST. This served as a controlled model system to delineate mechanisms of sensitivity and resistance to BET bromodomain inhibitors in this disease. Results: Here, we show that a malignant progression–associated increase in BRD4 protein levels corresponds to partial sensitivity to BET inhibition in MPNST. Strikingly, genetic depletion of BRD4 protein levels synergistically sensitized MPNST cells to diverse BET inhibitors in culture and in vivo. Conclusions: Collectively, MPNST sensitivity to combination genetic and pharmacologic inhibition of BRD4 revealed the presence of a unique addiction to BRD4 in MPNST. Our discovery that a synthetic lethality exists between BET inhibition and reduced BRD4 protein levels nominates MPNST for the investigation of emerging therapeutic interventions such as proteolysis-targeting chimeras (PROTACs) that simultaneously target bromodomain activity and BET protein abundance.",
author = "Cooper, {Jonathan M.} and Patel, {Amish J.} and Zhiguo Chen and {Liao Ph.D.}, {Chung Ping} and Kun Chen and Juan Mo and Yong Wang and Le, {Lu Q}",
year = "2019",
month = "6",
day = "1",
doi = "10.1158/1078-0432.CCR-18-2437",
language = "English (US)",
volume = "25",
pages = "3404--3416",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Overcoming BET inhibitor resistance in malignant peripheral nerve sheath tumors

AU - Cooper, Jonathan M.

AU - Patel, Amish J.

AU - Chen, Zhiguo

AU - Liao Ph.D., Chung Ping

AU - Chen, Kun

AU - Mo, Juan

AU - Wang, Yong

AU - Le, Lu Q

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Purpose: BET bromodomain inhibitors have emerged as a promising therapy for numerous cancer types in preclinical studies, including neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumor (MPNST). However, potential mechanisms underlying resistance to these inhibitors in different cancers are not completely understood. In this study, we explore new strategy to overcome BET inhibitor resistance in MPNST. Experimental Design: Through modeling tumor evolution by studying genetic changes underlying the development of MPNST, a lethal sarcoma with no effective medical treatment, we identified a targetable addiction to BET bromodomain family member BRD4 in MPNST. This served as a controlled model system to delineate mechanisms of sensitivity and resistance to BET bromodomain inhibitors in this disease. Results: Here, we show that a malignant progression–associated increase in BRD4 protein levels corresponds to partial sensitivity to BET inhibition in MPNST. Strikingly, genetic depletion of BRD4 protein levels synergistically sensitized MPNST cells to diverse BET inhibitors in culture and in vivo. Conclusions: Collectively, MPNST sensitivity to combination genetic and pharmacologic inhibition of BRD4 revealed the presence of a unique addiction to BRD4 in MPNST. Our discovery that a synthetic lethality exists between BET inhibition and reduced BRD4 protein levels nominates MPNST for the investigation of emerging therapeutic interventions such as proteolysis-targeting chimeras (PROTACs) that simultaneously target bromodomain activity and BET protein abundance.

AB - Purpose: BET bromodomain inhibitors have emerged as a promising therapy for numerous cancer types in preclinical studies, including neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumor (MPNST). However, potential mechanisms underlying resistance to these inhibitors in different cancers are not completely understood. In this study, we explore new strategy to overcome BET inhibitor resistance in MPNST. Experimental Design: Through modeling tumor evolution by studying genetic changes underlying the development of MPNST, a lethal sarcoma with no effective medical treatment, we identified a targetable addiction to BET bromodomain family member BRD4 in MPNST. This served as a controlled model system to delineate mechanisms of sensitivity and resistance to BET bromodomain inhibitors in this disease. Results: Here, we show that a malignant progression–associated increase in BRD4 protein levels corresponds to partial sensitivity to BET inhibition in MPNST. Strikingly, genetic depletion of BRD4 protein levels synergistically sensitized MPNST cells to diverse BET inhibitors in culture and in vivo. Conclusions: Collectively, MPNST sensitivity to combination genetic and pharmacologic inhibition of BRD4 revealed the presence of a unique addiction to BRD4 in MPNST. Our discovery that a synthetic lethality exists between BET inhibition and reduced BRD4 protein levels nominates MPNST for the investigation of emerging therapeutic interventions such as proteolysis-targeting chimeras (PROTACs) that simultaneously target bromodomain activity and BET protein abundance.

UR - http://www.scopus.com/inward/record.url?scp=85066634641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066634641&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-2437

DO - 10.1158/1078-0432.CCR-18-2437

M3 - Article

C2 - 30796033

AN - SCOPUS:85066634641

VL - 25

SP - 3404

EP - 3416

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -